Pseudomonas is a common and virulent respiratory bacteria in patients with Cystic Fibrosis (CF). With time, the infection with Pseudomonas becomes chronic and very difficult to eradicate. The standard treatment of chronic Pseudomonas infection is inhaled Tobramycin which is given every other month.. Inhalation of Tobramycin was proven as an effective treatment that improves the respiratory function and reduces the concentration of bacteria in the sputum. However, inhaled treatment lasts between 15 to 30 minutes twice a day and therefore adherence is a major problem. The effect of switching from inhalation treatment to inhaler treatment on patient's adherence and quality of life has not been studied.
Study Type
OBSERVATIONAL
Enrollment
40
Safra Children's Hospital, Sheba Medical Center
Ramat Gan, Israel
Improvement in quality of life
Time frame: 1 year
Difference in exacerbation events
To be measured by: Worsening of CF symptoms such as coughing, sputum, deterioration in FEV1, all of which require hospitalization
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.